Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ESMO Annual Congress Coverage

 

The European Society for Medical Oncology annual congress for 2023 takes place in Madrid, Spain from 20-24 October. This page is your one-stop shop for all of Scrip's conference coverage, including preview and post-meeting analysis. You can also find archive content from previous meetings here.


China Approval For Akeso’s Bispecific But ASCO Data Unnerve Investors

Ivonescimab in combination with chemotherapy reduced the risk of disease progression or death by 54% versus placebo in EGFR-mutated, non-squamous NSCLC after failed EGFR inhibitor treatment. However, the progression-free survival data did little to satisfy investors’ demand for clear benefits versus competitors. 

China Approvals

AstraZeneca And Daiichi Follow Gilead’s Lead

The partners’ antibody-drug conjugate datopotamab deruxtecan misses on overall survival, potentially limiting its market reach.

Clinical Trials Commercial

Amgen’s Imdelltra Wins FDA Nod In Underserved SCLC Population

The DLL3-targeting bispecific antibody won accelerated approval in extensive-stage small-cell lung cancer among patients treated with platinum chemotherapy.

Approvals ImmunoOncology

Pipeline Watch: Six Approvals And 12 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval

The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.

Approvals Business Strategies

Pipeline Watch: Four Approvals And 21 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Five Clinical Trial Hits Of 2023

The biopharma industry’s fate lies largely in its R&D successes and failures. Here, Scrip looks at five clinical trial successes that will shape their sponsors’ futures and got readers clicking in 2023.

Scrip Perspectives Clinical Trials

BMS Bets $8.4bn On Biokin’s Bispecific ADC

In a record licensing deal involving a single biopharma asset from China, Biokin and its US subsidiary SystImmune will receive up to $8.4bn from BMS, including $800m upfront, for a bispecific ADC with broad oncology potential. 

China Deals

Pipeline Watch: 10 Approvals And 22 Phase III Trial Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Olema Boosts Its Partnering Position With SERD Combo Data

Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.

Clinical Trials Companies

SpringWorks’ Ogsiveo Is First-Ever US FDA-Approved Drug For Desmoid Tumors

SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply. 

Approvals Launches

AstraZeneca Wins The AKT Race With Truqap

The UK big pharma gets a first-in-class approval in breast cancer, but a challenger is emerging.

Approvals Cancer

Merck KGaA Sticks With Structure, Eyes Smaller Healthcare Deals

There may be a trend towards spinning off business units but Merck continues to sees its three-pillar structure as providing the best protection from downturns in any individual segment.

Sales & Earnings Business Strategies

Finance Watch: Lexeo Launches 20th US Biopharma IPO In 2023

Public Company Edition: Lexeo raised $100m to advance its genetic medicines. Also, Blue Owl Capital acquired funds managed by Cowen Healthcare Investments, gaining about $1bn in life science assets, BMS priced $4.5bn in notes to fund its Mirati purchase and Viridian raised $185m in a private placement.

Financing Growth

A Gloomy Outlook On Macro Trends From Industry CEOs

Pfizer CEO Albert Bourla, Eli Lilly CEO David Ricks and Seagen CEO David Epstein discussed pressing issues facing the pharmaceutical industry at the recent Galien Forum.

Leadership Politics

Pipeline Watch: Updates from ESMO and CTAD Dominate

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All
UsernamePublicRestriction

Register